Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy

BACKGROUND: Treatment of uterine serous carcinoma (USC) is challenging; effective treatment options for metastatic and recurrent disease are needed. CASE: A 68-year-old woman with recurrent, metastatic, USC overexpressing HER2/neu experienced durable response to the antibody drug conjugate (ADC) tra...

Descripción completa

Detalles Bibliográficos
Autores principales: McNamara, Blair, Bellone, Stefania, Demirkiran, Cem, Hartwich, Tobias Max Philipp, Santin, Alessandro D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Survey Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265462/
https://www.ncbi.nlm.nih.gov/pubmed/37325293
http://dx.doi.org/10.1016/j.gore.2023.101219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265462/
https://www.ncbi.nlm.nih.gov/pubmed/37325293
http://dx.doi.org/10.1016/j.gore.2023.101219

Ejemplares similares